The role of inflammation in core features of depression: Insights from paradigms using exogenously-induced inflammation

Neuroscience and Biobehavioral Reviews

Volumn 94, Issue , 2018, Pages 219-237

  Dooley, Larissa N ^a   Kuhlman, Kate R ^b,c   Robles, Theodore F ^c,d   Eisenberger, Naomi I ^c,d   Craske, Michelle G ^d   Bower, Julienne E ^c,d  

^a SEE Change Institute   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cognitive control; Depression; Endophenotype; Inflammation; Mood; Reward; Somatic

Indexed keywords

ALPHA INTERFERON; CORTICOTROPIN RELEASING FACTOR; DOPAMINE; GLUTAMIC ACID; INDOLEAMINE 2,3 DIOXYGENASE; SEROTONIN; TRYPTOPHAN; TYPHOID VACCINE;

ANHEDONIA; CLINICAL FEATURE; DEPRESSION; DISEASE ASSOCIATION; ENDOPHENOTYPE; EXECUTIVE FUNCTION; FATIGUE; HEPATITIS C; HUMAN; INFLAMMATION; INFORMATION PROCESSING; INSOMNIA; MALIGNANT NEOPLASM; NEUROBIOLOGY; NEUROPSYCHOLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PSYCHOMOTOR RETARDATION; PSYCHOSOMATICS; REVIEW; REWARD; STRESS; TRYPTOPHAN METABOLISM; ANIMAL; IMMUNOLOGY; PATHOPHYSIOLOGY; PSYCHOLOGY;

ANIMALS; DEPRESSION; DEPRESSIVE DISORDER; HUMANS; INFLAMMATION;

EID: 85053788830     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2018.09.006     Document Type: Review

References (246)

1. Addington, A.M., Gallo, J.J., Ford, D.E., Eaton, W.W., Epidemiology of unexplained fatigue and major depression in the community: the Baltimore ECA follow-up, 1981-1994. Psychol. Med. (Paris) 31 (2001), 1037–1044, 10.1017/S0033291701004214.
2. Alam, M.N., McGinty, D., Bashir, T., Kumar, S., Imeri, L., Opp, M.R., Szymusiak, R., Interleukin-1b modulates state-dependent discharge activity of preoptic area and basal forebrain neurons: role in sleep regulation. Eur. J. Neurosci. 20 (2004), 207–216, 10.1111/j.1460-9568.2004.03469.x.
3. Alvarez, J.A., Emory, E., Executive function and the frontal lobes: a meta-analytic review. Neuropsychol. Rev. 16 (2006), 17–42, 10.1007/s11065-006-9002-x.
4. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders. 2013, 10.1176/appi.books.9780890425596.744053.
5. Amodio, P., De Toni, E.N., Cavalletto, L., Mapelli, D., Bernardinello, E., Del Piccolo, F., Bergamelli, C., Costanzo, R., Bergamaschi, F., Poma, S.Z., Chemello, L., Gatta, A., Perini, G., Mood, cognition and EEG changes during interferon-a treatment for chronic hepatitis C. J. Affect. Disord. 84 (2005), 93–98, 10.1016/j.jad.2004.09.004.
6. Andreasen, A.S., Krabbe, K.S., Krogh-Madsen, R., Taudorf, S., Pedersen, B.K., Moller, K., Human endotoxemia as a model of systemic inflammation. Curr. Med. Chem. 15 (2008), 1697–1705, 10.2174/092986708784872393.
7. Anisman, H., Matheson, K., Stress, depression, and anhedonia: caveats concerning animal models. Neurosci. Biobehav. Rev. 29 (2005), 525–546, 10.1016/j.neubiorev.2005.03.007.
8. Ankarcrona, M., Dypbukt, J.M., Bonfoco, E., Zhivotovsky, B., Orrenius, S., Lipton, S.A., Nicotera, P., Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron 15 (1995), 961–973.
9. Arnold, L.M., Understanding fatigue in major depressive disorder and other medical disorders. Psychosomatics 49 (2008), 185–190, 10.1176/appi.psy.49.3.185.
10. Banich, M.T., Executive function: the search for an integrated account. Curr. Dir. Psychol. Sci. 18 (2009), 89–94, 10.1111/j.1467-8721.2009.01615.x.
11. Banks, W.A., Erickson, M.A., The blood–brain barrier and immune function and dysfunction. Neurobiol. Dis. Special Issue: Blood Brain Barrier 37 (2010), 26–32, 10.1016/j.nbd.2009.07.031.
12. Beck, A.T., Cognition and Psychotherapy. 2004, Springer Science & Business Media, New York.
13. Beevers, C.G., Clasen, P., Stice, E., Schnyer, D., Depression symptoms and cognitive control of emotion cues: a functional magnetic resonance imaging study. Neuroscience 167 (2010), 97–103, 10.1016/j.neuroscience.2010.01.047.
14. Bench, C.J., Friston, K.J., Brown, R.G., Frackowiak, R.S., Dolan, R.J., Regional cerebral blood flow in depression measured by positron emission tomography: the relationship with clinical dimensions. Psychol. Med. (Paris) 23 (1993), 579–590, 10.1017/S0033291700025368.
15. Berridge, K.C., Kringelbach, M.L., Affective neuroscience of pleasure: reward in humans and animals. Psychopharmacology (Berl.) 199 (2008), 457–480, 10.1007/s00213-008-1099-6.
16. Biesheuvel-Leliefeld, K.E.M., Kok, G.D., Bockting, C.L.H., Cuijpers, P., Hollon, S.D., Marwijk, H.W.J., van, Smit, F., Effectiveness of psychological interventions in preventing recurrence of depressive disorder: meta-analysis and meta-regression. J. Affect. Disord. 174 (2015), 400–410, 10.1016/j.jad.2014.12.016.
17. Bilbo, S.D., Schwarz, J.M., The immune system and developmental programming of brain and behavior. Front. Neuroendocrinol. 33 (2012), 267–286, 10.1016/j.yfrne.2012.08.006.
18. Bogdan, R., Pizzagalli, D.A., The heritability of hedonic capacity and perceived stress: a twin study evaluation of candidate depressive phenotypes. Psychol. Med. (Paris) 39 (2009), 211–218, 10.1017/S0033291708003619.
19. Borkulo, C., van, Boschloo, L., Borsboom, D., Penninx, B.W.J.H., Waldorp, L.J., Schoevers, R.A., Association of symptom network structure with the course of depression. JAMA Psychiatry 72 (2015), 1219–1226, 10.1001/jamapsychiatry.2015.2079.
20. Borsboom, D., Cramer, A.O.J., Network analysis: an integrative approach to the structure of psychopathology. Annu. Rev. Clin. Psychol. 9 (2013), 91–121, 10.1146/annurev-clinpsy-050212-185608.
21. Bower, J.E., Ganz, P.A., Tao, M.L., Hu, W., Belin, T.R., Sepah, S., Cole, S., Aziz, N., Inflammatory biomarkers and fatigue during radiation therapy for breast and prostate cancer. Clin. Cancer Res. 15 (2009), 5534–5540, 10.1158/1078-0432.CCR-08-2584.
22. Bower, J.E., Greendale, G., Crosswell, A.D., Garet, D., Sternlieb, B., Ganz, P.A., Irwin, M.R., Olmstead, R., Arevalo, J., Cole, S.W., Yoga reduces inflammatory signaling in fatigued breast cancer survivors: a randomized controlled trial. Psychoneuroendocrinology 43 (2014), 20–29, 10.1016/j.psyneuen.2014.01.019.
23. Boyle, C.C., Ganz, P.A., Van Dyk, K.M., Bower, J.E., Inflammation and attentional bias in breast cancer survivors. Brain Behav. Immun. 66 (2017), 85–88, 10.1016/j.bbi.2017.05.016.
24. Bromet, E., Andrade, L.H., Hwang, I., Sampson, N.A., Alonso, J., de Girolamo, G., de Graaf, R., Demyttenaere, K., Hu, C., Iwata, N., Karam, A.N., Kaur, J., Kostyuchenko, S., Lépine, J.-P., Levinson, D., Matschinger, H., Mora, M.E.M., Browne, M.O., Posada-Villa, J., Viana, M.C., Williams, D.R., Kessler, R.C., Cross-national epidemiology of DSM-IV major depressive episode. BMC Med., 9, 2011, 90, 10.1186/1741-7015-9-90.
25. Brydon, L., Harrison, N.A., Walker, C., Steptoe, A., Critchley, H.D., Peripheral inflammation is associated with altered substantia nigra activity and psychomotor slowing in humans. Biol. Psychiatry 63 (2008), 1022–1029, 10.1016/j.biopsych.2007.12.007.
26. Brydon, L., Walker, C., Wawrzyniak, A., Whitehead, D., Okamura, H., Yajima, J., Tsuda, A., Steptoe, A., Synergistic effects of psychological and immune stressors on inflammatory cytokine and sickness responses in humans. Brain Behav. Immun. 23 (2009), 217–224, 10.1016/j.bbi.2008.09.007.
27. Bunzeck, N., Düzel, E., Absolute coding of stimulus novelty in the human substantia nigra/VTA. Neuron 51 (2006), 369–379, 10.1016/j.neuron.2006.06.021.
28. Butler, G., Mathews, A., Cognitive processes in anxiety. Adv. Behav. Res. Ther. 5 (1983), 51–62, 10.1016/0146-6402(83)90015-2.
29. Calabrese, F., Rossetti, A.C., Racagni, G., Gass, P., Riva, M.A., Molteni, R., Brain-derived neurotrophic factor: a bridge between inflammation and neuroplasticity. Front. Cell. Neurosci., 8, 2014, 10.3389/fncel.2014.00430.
30. Capuron, L., Miller, A.H., Cytokines and psychopathology: lessons from interferon-α. Biol. Psychiatry 56 (2004), 819–824, 10.1016/j.biopsych.2004.02.009.
31. Capuron, L., Ravaud, A., Dantzer, R., Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-alpha treatments in cancer patients. Psychosom. Med. 63 (2001), 376–386.
32. Capuron, L., Gumnick, J.F., Musselman, D.L., Lawson, D.H., Reemsnyder, A., Nemeroff, C.B., Miller, A.H., Neurobehavioral effects of interferon-α in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 26 (2002), 643–652, 10.1016/S0893-133X(01)00407-9.
33. Capuron, L., Raison, C.L., Musselman, D.L., Lawson, D.H., Nemeroff, C.B., Miller, A.H., Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am. J. Psychiatry 160 (2003), 1342–1345, 10.1176/appi.ajp.160.7.1342.
34. Capuron, L., Ravaud, A., Miller, A.H., Dantzer, R., Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain Behav. Immun. 18 (2004), 205–213, 10.1016/j.bbi.2003.11.004.
35. Capuron, L., Pagnoni, G., Demetrashvili, M.F., Lawson, D.H., Fornwalt, F.B., Woolwine, B., Berns, G.S., Nemeroff, C.B., Miller, A.H., Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy. Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 32 (2007), 2384–2392, 10.1038/sj.npp.1301362.
36. Capuron, L., Pagnoni, G., Drake, D.F., Woolwine, B.J., Spivey, J.R., Crowe, R.J., Votaw, J.R., Goodman, M.M., Miller, A.H., Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon alfa administration. Arch. Gen. Psychiatry 69 (2012), 1044–1053, 10.1001/archgenpsychiatry.2011.2094.
37. Caraceni, A., Gangeri, L., Martini, C., Belli, F., Brunelli, C., Baldini, M., Mascheroni, L., Lenisa, L., Cascinelli, N., Neurotoxicity of interferon-α in melanoma therapy: results from a randomized controlled trial. Cancer 83 (1998), 482–489, 10.1002/(SICI)1097-0142(19980801)83:3<482::AID-CNCR17>3.0.CO;2-S.
38. Carty, C.L., Heagerty, P., Nakayama, K., McClung, E.C., Lewis, J., Lum, D., Boespflug, E., McCloud-Gehring, C., Soleimani, B.R., Ranchalis, J., Bacus, T.J., Furlong, C.E., Jarvik, G.P., Inflammatory response after influenza vaccination in men with and without carotid artery disease. Arterioscler. Thromb. Vasc. Biol. 26 (2006), 2738–2744, 10.1161/01.ATV.0000248534.30057.b5.
39. Casper, R.C., Redmond, D.E., Katz, M.M., Schaffer, C.B., Davis, J.M., Koslow, S.H., Somatic symptoms in primary affective disorder: presence and relationship to the classification of depression. Arch. Gen. Psychiatry 42 (1985), 1098–1104, 10.1001/archpsyc.1985.01790340082012.
40. Castaneda, A.E., Tuulio-Henriksson, A., Marttunen, M., Suvisaari, J., Lonnqvist, J., A review on cognitive impairments in depressive and anxiety disorders with a focus on young adults. J. Affect. Disord. 106 (2008), 1–27, 10.1016/j.jad.2007.06.006.
41. Christian, L.M., Iams, J.D., Porter, K., Glaser, R., Inflammatory responses to trivalent influenza virus vaccine among pregnant women. Vaccine 29 (2011), 8982–8987, 10.1016/j.vaccine.2011.09.039.
42. Cipriani, A., Furukawa, T.A., Salanti, G., Chaimani, A., Atkinson, L.Z., Ogawa, Y., Leucht, S., Ruhe, H.G., Turner, E.H., Higgins, J.P.T., Egger, M., Takeshima, N., Hayasaka, Y., Imai, H., Shinohara, K., Tajika, A., Ioannidis, J.P.A., Geddes, J.R., Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. Lancet 391 (2018), 1357–1366, 10.1016/S0140-6736(17)32802-7.
43. Craske, M.G., The R-Doc initiative: science and practice. Depress. Anxiety 29 (2012), 253–256, 10.1002/da.21930.
44. Craske, M.G., Meuret, A.E., Ritz, T., Treanor, M., Dour, H.J., Treatment for anhedonia: a neuroscience driven approach. Depress. Anxiety 33 (2016), 927–938, 10.1002/da.22490.
45. Cuthbert, B., Insel, T., Commentary on “the need for patient-subjective data in the the Data of Diagnosis : new approaches to psychiatric classification”. Psychiatry 73 (2010), 311–315, 10.1521/psyc.2010.73.4.311.
46. Danese, A., Moffitt, T.E., Pariante, C.M., Ambler, A., Poulton, R., Caspi, A., Elevated inflammation levels in depressed adults with a history of childhood maltreatment. Arch. Gen. Psychiatry 65 (2008), 409–415, 10.1001/archpsyc.65.4.409.
47. Dantzer, R., Walker, A.K., Is there a role for glutamate-mediated excitotoxicity in inflammation-induced depression?. J. Neural Transm. Vienna (Vienna) 1996:121 (2014), 925–932, 10.1007/s00702-014-1187-1.
48. Dantzer, R., O'Connor, J.C., Freund, G.G., Johnson, R.W., Kelley, K.W., From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9 (2008), 46–56, 10.1038/nrn2297.
49. Dantzer, R., O'Connor, J.C., Lawson, M.A., Kelley, K.W., Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 36 (2011), 426–436, 10.1016/j.psyneuen.2010.09.012.
50. Dantzer, R., Heijnen, C.J., Kavelaars, A., Laye, S., Capuron, L., The neuroimmune basis of fatigue. Trends Neurosci. 37 (2014), 39–46, 10.1016/j.tins.2013.10.003.
51. Davis, M.C., Lemery-Chalfant, K., Yeung, E.W., Luecken, L.J., Zautra, A.J., Irwin, M.R., Interleukin-6 and depressive mood symptoms: mediators of the association between childhood abuse and cognitive performance in middle-aged adults. Ann. Behav. Med., 2018, 10.1093/abm/kay014.
52. De La Garza, R., Endotoxin- or pro-inflammatory cytokine-induced sickness behavior as an animal model of depression: focus on anhedonia. Neurosci. Biobehav. Rev. 29 (2005), 761–770, 10.1016/j.neubiorev.2005.03.016.
53. de Rooij, S.R., Schene, A.H., Phillips, D.I., Roseboom, T.J., Depression and anxiety: associations with biological and perceived stress reactivity to a psychological stress protocol in a middle-aged population. Psychoneuroendocrinology 35 (2010), 866–877, 10.1016/j.psyneuen.2009.11.011.
54. Dearing, K.F., Gotlib, I.H., Interpretation of ambiguous information in girls at risk for depression. J. Abnorm. Child Psychol. 4 (2009), 79–91, 10.1126/scisignal.2001449.Engineering.
55. Del Arco, A., Mora, F., Prefrontal cortex-nucleus accumbens interaction: in vivo modulation by dopamine and glutamate in the prefrontal cortex. Pharmacol. Biochem. Behav. 90 (2008), 226–235, 10.1016/j.pbb.2008.04.011.
56. DellaGioia, N., Hannestad, J., A critical review of human endotoxin administration as an experimental paradigm of depression. Neurosci. Biobehav. Rev. 34 (2010), 130–143, 10.1016/j.neubiorev.2009.07.014.
57. DeLuca, J., Genova, H.M., Capili, E.J., Wylie, G.R., Functional neuroimaging of fatigue. Phys. Med. Rehabil. Clin. N. Am., Fatigue 20 (2009), 325–337, 10.1016/j.pmr.2008.12.007.
58. Demyttenaere, K., De Fruyt, J., Stahl, S.M., The many faces of fatigue in major depressive disorder. Int. J. Neuropsychopharmacol. 8 (2005), 93–105, 10.1017/S1461145704004729.
59. Deveney, C.M., Deldin, P.J., Memory of faces: a slow wave ERP study of major depression. Emotion 4 (2004), 295–304, 10.1037/1528-3542.4.3.295r2004-18367-008.
60. Disner, S.G., Beevers, C.G., Haigh, E.A., Beck, A.T., Neural mechanisms of the cognitive model of depression. Nat. Rev. Neurosci. 12 (2011), 467–477, 10.1038/nrn3027.
61. Dobryakova, E., Genova, H.M., DeLuca, J., Wylie, G.R., The dopamine imbalance hypothesis of fatigue in multiple sclerosis and other neurological disorders. Front. Neurol., 6, 2015, 10.3389/fneur.2015.00052.
62. Dooley, L.N., Ganz, P.A., Cole, S.W., Crespi, C.M., Bower, J.E., Val66Met BDNF polymorphism as a vulnerability factor for inflammation-associated depressive symptoms in women with breast cancer. J. Affect. Disord. 197 (2016), 43–50, 10.1016/j.jad.2016.02.059.
63. Dowell, N.G., Cooper, E.A., Tibble, J., Voon, V., Critchley, H.D., Cercignani, M., Harrison, N.A., Acute changes in striatal microstructure predict the development of interferon-alpha induced fatigue. Biol. Psychiatry 79 (2016), 320–328, 10.1016/j.biopsych.2015.05.015.
64. Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E.K., Lanctôt, K.L., A meta-analysis of cytokines in Major Depression. Biol. Psychiatry, Cortical Inhibitory Deficits in Depression 67 (2010), 446–457, 10.1016/j.biopsych.2009.09.033.
65. Drevets, W.C., Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr. Opin. Neurobiol. 11 (2001), 240–249, 10.1016/S0959-4388(00)00203-8.
66. Drozdz, W., Borkowska, A., Halota, W., Rybakowski, J.K., Depressive symptoms and cognitive dysfunction in patients with hepatitis C treated with interferon-α and ribavirine. Arch. Psychiatry, 2008, 85–91.
67. Dunlop, K., Hanlon, C.A., Downar, J., Noninvasive brain stimulation treatments for addiction and major depression. Ann. N. Y. Acad. Sci. 1394 (2017), 31–54, 10.1111/nyas.12985.
68. Dunn, B.D., Dalgleish, T., Lawrence, A.D., Cusack, R., Ogilvie, A.D., Categorical and dimensional reports of experienced affect to emotion-inducing pictures in depression. J. Abnorm. Psychol. 113 (2004), 654–660, 10.1037/0021-843X.113.4.654.
69. Dunn, A.J., Swiergiel, A.H., De Beaurepaire, R., Cytokines as mediators of depression: what can we learn from animal studies?. Neurosci. Biobehav. Rev. 29 (2005), 891–909, 10.1016/j.neubiorev.2005.03.023.
70. Eisenberger, N.I., Cole, S.W., Social neuroscience and health: neurophysiological mechanisms linking social ties with physical health. Nat. Neurosci. 15 (2012), 669–674, 10.1038/nn.3086.
71. Eisenberger, N.I., Inagaki, T.K., Rameson, L.T., Mashal, N.M., Irwin, M.R., An fMRI study of cytokine-induced depressed mood and social pain: the role of sex differences. NeuroImage 47 (2009), 881–890, 10.1016/j.neuroimage.2009.04.040.
72. Eisenberger, N.I., Berkman, E.T., Inagaki, T.K., Rameson, L.T., Mashal, N.M., Irwin, M.R., Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward. Biol. Psychiatry 68 (2010), 748–754, 10.1016/j.biopsych.2010.06.010.
73. Eisenberger, N.I., Inagaki, T.K., Mashal, N.M., Irwin, M.R., Inflammation and social experience: an inflammatory challenge induces feelings of social disconnection in addition to depressed mood. Brain Behav. Immun. 24 (2010), 558–563, 10.1016/j.bbi.2009.12.009.
74. Eisenberger, N.I., Moieni, M., Inagaki, T.K., Muscatell, K.A., Irwin, M.R., In sickness and in health: the co-regulation of inflammation and social behavior. Neuropsychopharmacology, 2016, 1–12, 10.1038/npp.2016.141.
75. Epstein, J., Pan, H., Kocsis, J.H., Yang, Y., Butler, T., Chusid, J., Hochberg, H., Murrough, J., Strohmayer, E., Stern, E., Silbersweig, D.A., Lack of ventral striatal response to positive stimuli in depressed versus normal subjects. Am. J. Psychiatry 163 (2006), 1784–1790, 10.1176/appi.ajp.163.10.1784.
76. Etkin, A., Egner, T., Kalisch, R., Emotional processing in anterior cingulate and medial prefrontal. Trends Cogn. Sci. (Regul. Ed.) 15 (2011), 85–93, 10.1016/j.tics.2010.11.004.Emotional.
77. Felger, J.C., The role of dopamine in inflammation-associated depression: mechanisms and therapeutic implications. Curr. Top. Behav. Neurosci. 31 (2017), 199–219, 10.1007/7854_2016_13.
78. Felger, J.C., Treadway, M.T., Inflammation effects on motivation and motor activity: role of dopamine. Neuropsychopharmacol. 42 (2016), 1–88, 10.1038/npp.2016.143.
79. Felger, J.C., Mun, J., Kimmel, H.L., Nye, J.A., Drake, D.F., Hernandez, C.R., Freeman, A.A., Rye, D.B., Goodman, M.M., Howell, L.L., Miller, A.H., Chronic interferon- a decreases dopamine 2 receptor binding and striatal dopamine release in association with anhedonia-like behavior in nonhuman primates. Neuropsychopharmacology 38 (2013), 2179–2187, 10.1038/npp.2013.115.
80. Fontana, R.J., Bieliauskas, L.A., Lindsay, K.L., Back-Madruga, C., Wright, E.C., Snow, K.K., Lok, A.S.F., Kronfol, Z., Padmanabhan, L., Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C. Hepatology 45 (2007), 1154–1163, 10.1002/hep.21633.
81. Frank, M.G., Watkins, L.R., Maier, S.F., Stress-induced glucocorticoids as a neuroendocrine alarm signal of danger. Brain Behav. Immun., 33, 2013, 1, 10.1016/j.bbi.2013.02.004.
82. Fried, E.I., Nesse, R.M., Depression is not a consistent syndrome : an investigation of unique symptom patterns in the STAR * D study. J. Affect. Disord. 172 (2015), 96–102, 10.1016/j.jad.2014.10.010.
83. Friedman, N.P., Miyake, A., Young, S.E., DeFries, J.C., Corley, R.P., Hewitt, J.K., Individual differences in executive functions are almost entirely genetic in origin. J. Exp. Psychol. Gen. 137 (2008), 201–225, 10.1037/0096-3445.137.2.201.
84. Fu, C.H., Williams, S.C., Cleare, A.J., Brammer, M.J., Walsh, N.D., Kim, J., Andrew, C.M., Pich, E.M., Williams, P.M., Reed, L.J., Mitterschiffthaler, M.T., Suckling, J., Bullmore, E.T., Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, event-related functional magnetic resonance imaging study. Arch. Gen. Psychiatry 61 (2004), 877–889, 10.1001/archpsyc.61.9.877.
85. Garvey, M.J., Mungas, D., Tollefson, G.D., Hypersomnia in major depressive disorders. J. Affect. Disord. 6 (1984), 283–286.
86. Gimeno, D., Kivimäki, M., Brunner, E.J., Elovainio, M., De Vogli, R., Steptoe, A., Kumari, M., Lowe, G.D.O., Rumley, A., Marmot, M.G., Ferrie, J.E., Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study. Psychol. Med. (Paris) 39 (2009), 413–423, 10.1017/S0033291708003723.
87. Glahn, D.C., Curran, J.E., Winkler, A.M., Carless, M.A., Kent, J.W., Charlesworth, J.C., Johnson, M.P., Göring, H.H.H., Cole, S.A., Dyer, T.D., Moses, E.K., Olvera, R.L., Kochunov, P., Duggirala, R., Fox, P.T., Almasy, L., Blangero, J., High dimensional endophenotype ranking in the search for major depression risk genes. Biol. Psychiatry 71 (2012), 6–14, 10.1016/j.biopsych.2011.08.022.
88. Goldstein, B.L., Klein, D.N., A review of selected candidate endophenotypes for depression. Clin. Psychol. Rev. 34 (2014), 417–427, 10.1016/j.cpr.2014.06.003.
89. Goshen, I., Yirmiya, R., Interleukin-1 (IL-1): a central regulator of stress responses. Front. Neuroendocrinol. 30 (2009), 30–45, 10.1016/j.yfrne.2008.10.001.
90. Gotlib, I.H., Hamilton, J.P., Neuroimaging and depression: current status and unresolved issues. Curr. Dir. Psychol. Sci. 17 (2008), 159–163, 10.1111/j.1467-8721.2008.00567.x.
91. Gotlib, I.H., Joormann, J., Cognition and depression: current status and future directions. Annu. Rev. Clin. Psychol. 6 (2010), 285–312, 10.1146/annurev.clinpsy.121208.131305.
92. Gotlib, I.H., Hamilton, J.P., Cooney, R.E., Singh, M.K., Henry, M.L., Joormann, J., Neural processing of reward and loss in girls at risk for major depression. Arch. Gen. Psychiatry 67 (2010), 380–387, 10.1001/archgenpsychiatry.2010.13.
93. Gottesman, I.I., Gould, T.D., The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiatry 160 (2003), 636–645, 10.1176/appi.ajp.160.4.636.
94. Gould, T.D., Gottesman, I.I., Psychiatric endophenotypes and the development of valid animal models. Genes Brain Behav. 5 (2006), 113–119, 10.1111/j.1601-183X.2005.00186.x.
95. Grigoleit, J.S., Oberbeck, J.R., Lichte, P., Kobbe, P., Wolf, O.T., Montag, T., Rey, A., del Gizewski, E.R., Engler, H., Schedlowski, M., Lipopolysaccharide-induced experimental immune activation does not impair memory functions in humans. Neurobiol. Learn. Mem. 94 (2010), 561–567, 10.1016/j.nlm.2010.09.011.
96. Grigoleit, J.-S., Kullmann, J.S., Wolf, O.T., Hammes, F., Wegner, A., Jablonowski, S., Engler, H., Gizewski, E., Oberbeck, R., Schedlowski, M., Dose-dependent effects of endotoxin on neurobehavioral functions in humans. PLoS One, 6, 2011, e28330, 10.1371/journal.pone.0028330.
97. Haapakoski, R., Mathieu, J., Ebmeier, K.P., Alenius, H., Kivimäki, M., Cumulative meta-analysis of interleukins 6 and 1β tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. Brain Behav. Immun., 49, 2015, 206.
98. Hammar, A., Ardal, G., Cognitive functioning in major depression–a summary. Front. Hum. Neurosci., 3, 2009, 26, 10.3389/neuro.09.026.2009.
99. Haroon, E., Miller, A.H., Inflammation effects on brain glutamate in depression: mechanistic considerations and treatment implications. Curr. Top. Behav. Neurosci. 31 (2017), 173–198, 10.1007/7854_2016_40.
100. Haroon, E., Raison, C.L., Miller, A.H., Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 37 (2012), 137–162, 10.1038/npp.2011.205.
101. Harrison, N.A., Brydon, L., Walker, C., Gray, M.A., Steptoe, A., Critchley, H.D., Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol. Psychiatry 66 (2009), 407–414, 10.1016/j.biopsych.2009.03.015.
102. Harrison, N.A., Doeller, C.F., Voon, V., Burgess, N., Critchley, H.D., Peripheral inflammation acutely impairs human spatial memory via actions on medial temporal lobe glucose metabolism. Biol. Psychiatry 76 (2014), 585–593, 10.1016/j.biopsych.2014.01.005.
103. Harrison, N.A., Cercignani, M., Voon, V., Critchley, H.D., Effects of inflammation on hippocampus and substantia nigra responses to novelty in healthy human participants. Neuropsychopharmacology 40 (2015), 831–838, 10.1038/npp.2014.222.
104. Harvey, P.-O., Pruessner, J., Czechowska, Y., Lepage, M., Individual differences in trait anhedonia: a structural and functional magnetic resonance imaging study in non-clinical subjects. Mol. Psychiatry 12 (2007), 767–775, 10.1038/sj.mp.4002021.
105. Hasler, G., Drevets, W.C., Manji, H.K., Charney, D.S., Discovering endophenotypes for major depression. Neuropsychopharmacology 29 (2004), 1765–1781, 10.1038/sj.npp.1300506.
106. Hasler, G., Drevets, W.C., Gould, T.D., Gottesman, I.I., Manji, H.K., Toward constructing an endophenotype strategy for bipolar disorders. Biol. Psychiatry 60 (2006), 93–105, 10.1016/j.biopsych.2005.11.006.
107. He, J., Hsuchou, H., He, Y., Kastin, A.J., Wang, Y., Pan, W., Sleep restriction impairs blood-brain barrier function. J. Neurosci. 34 (2014), 14697–14706, 10.1523/JNEUROSCI.2111-14.2014.
108. Heller, A., Johnstone, T., Shackman, A., Light, S., Peterson, M., Kolden, G., Kalin, N., Davidson, R., Reduced capacity to sustain positive emotion in major depression reflects diminished maintenance of fronto-striatal brain activation. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 22445–22450, 10.1073/pnas.0910651106.
109. Hermann, D.M., Mullington, J., Hinze-Selch, D., Schreiber, W., Galanos, C., Pollmächer, T., Endotoxin-induced changes in sleep and sleepiness during the day. Psychoneuroendocrinology 23 (1998), 427–437, 10.1016/S0306-4530(98)00030-4.
110. Hetta, J., Rimón, R., Almqvist, M., Mood alterations and sleep. Ann. Clin. Res. 17 (1985), 252–256.
111. Hilsabeck, R.C., Hassanein, T.I., Ziegler, E.A., Carlson, M.D., Perry, W., Effect of interferon-alpha on cognitive functioning in patients with chronic hepatitis C. J. Int. Neuropsychol. Soc. JINS 11 (2005), 16–22, 10.1017/S1355617705050022.
112. Hingorani, A.D., Bhagat, K., Palacios, M., Griffin, G.E., MacAllister, R.J., Vallance, P., Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Brit. J. Pharmacol., 126, 1999 U31-U31.
113. Howren, M.B., Lamkin, D.M., Suls, J., Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 71 (2009), 171–186, 10.1097/PSY.0b013e3181907c1b.
114. Huang, M., Su, S., Goldberg, J., Miller, A.H., Murrah, N.V., Shallenberger, L., Pimple, P., Bremner, J.D., Vaccarino, V., Pathway linking depression and inflammation: a 5-year longitudinal twin difference study. Circulation, 135, 2017, AMP074.
115. Imeri, L., Opp, M.R., How (and why) the immune system makes us sleep. Nat. Rev. Neurosci. 10 (2009), 199–210, 10.1038/nrn2576.
116. Inagaki, T.K., Muscatell, K.A., Irwin, M.R., Cole, S.W., Eisenberger, N.I., Inflammation selectively enhances amygdala activity to socially threatening images. NeuroImage 59 (2012), 3222–3226, 10.1016/j.neuroimage.2011.10.090.
117. Inagaki, T.K., Muscatell, K.A., Irwin, M.R., Moieni, M., Dutcher, J.M., Jevtic, I., Breen, E.C., Eisenberger, N.I., The role of the ventral striatum in inflammatory-induced approach toward support figures. Brain Behav. Immun. 44 (2015), 247–252, 10.1016/j.bbi.2014.10.006.
118. Insel, T., Cuthbert, B., Garvey, M., Heinssen, R., Pine, D.S., Quinn, K., Sanislow, C., Wang, P., Research Domain Criteria (RDoC): toward a new classification framework for research on mental disorders. Am. J. Psychiatry 167 (2010), 748–751, 10.1176/appi.ajp.2010.09091379.
119. Irwin, M.R., Psychoneuroimmunology of depression: clinical implications. Brain Behav. Immun. 16 (2002), 1–16, 10.1006/brbi.2001.0654.
120. Janssen, H.L.A., Brouwer, J.T., van der Mast, R.C., Schalm, S.W., Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J. Hepatol. 21 (1994), 241–243, 10.1016/S0168-8278(05)80402-7.
121. Joormann, J., Quinn, M.E., Cognitive processes and emotion regulation in depression. Depress. Anxiety 31 (2014), 308–315, 10.1002/da.22264.
122. Kakade, S., Dayan, P., Dopamine: generalization and bonuses. Neural Netw. 15 (2002), 549–559, 10.1016/S0893-6080(02)00048-5.
123. Kanoski, S.E., Zhang, Y., Zheng, W., Davidson, T.L., The effects of a high-energy diet on hippocampal function and blood-brain barrier integrity in the rat. J. Alzheimers Dis. 21 (2010), 207–219, 10.3233/JAD-2010-091414.
124. Karshikoff, B., Sundelin, T., Lasselin, J., Role of inflammation in human fatigue: relevance of multidimensional assessments and potential neuronal mechanisms. Front. Immunol., 2017, 8.
125. Kato, K., Sullivan, P.F., Evengård, B., Pedersen, N.L., A population-based twin study of functional somatic syndromes. Psychol. Med. (Paris) 39 (2009), 497–505, 10.1017/S0033291708003784.
126. Keedwell, P.A., Andrew, C., Williams, S.C.R., Brammer, M.J., Phillips, M.L., The neural correlates of anhedonia in major depressive disorder. Biol. Psychiatry 58 (2005), 843–853, 10.1016/j.biopsych.2005.05.019.
127. Kendler, K.S., Neale, M.C., Kessler, R.C., Heath, A.C., Eaves, L.J., Familial influences on the clinical characteristics of major depression: a twin study. Acta Psychiatr. Scand. 86 (1992), 371–378, 10.1111/j.1600-0447.1992.tb03283.x.
128. Kenis, G., Maes, M., Effects of antidepressants on the production of cytokines. Int. J. Neuropsychopharmacol. 5 (2002), 401–412, 10.1017/S1461145702003164.
129. Kessler, R.C., Bromet, E.J., The epidemiology of depression across cultures. Annu. Rev. Public Health 34 (2013), 119–138, 10.1146/annurev-publhealth-031912-114409.
130. Köhler, O., Benros, M.E., Nordentoft, M., Farkouh, M.E., Iyengar, R.L., Mors, O., Krogh, J., Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry, 71, 2014, 1381, 10.1001/jamapsychiatry.2014.1611.
131. Korth, C., Mullington, J., Schreiber, W., Pollmächer, T., Influence of endotoxin on daytime sleep in humans. Infect. Immun. 64 (1996), 1110–1115.
132. Krabbe, K.S., Reichenberg, A., Yirmiya, R., Smed, A., Pedersen, B.K., Bruunsgaard, H., Low-dose endotoxemia and human neuropsychological functions. Brain. Behav. Immun. Phys. Activity Behav. Immun. Health 19 (2005), 453–460, 10.1016/j.bbi.2005.04.010.
133. Krause, A.J., Simon, E.B., Mander, B.A., Greer, S.M., Saletin, J.M., Goldstein-Piekarski, A.N., Walker, M.P., The sleep-deprived human brain. Nat. Rev. Neurosci., 18, 2017, 404.
134. Kroenke, K., Price, R.K., Symptoms in the community. Prevalence, classification, and psychiatric comorbidity. Arch. Intern. Med. 153 (1993), 2474–2480.
135. Kuehner, C., Gender differences in unipolar depression: an update of epidemiological findings and possible explanations. Acta Psychiatr. Scand. 108 (2003), 163–174, 10.1034/j.1600-0447.2003.00204.x.
136. Kuhlman, K.R., Chiang, J.J., Horn, S., Bower, J.E., Developmental psychoneuroendocrine and psychoneuroimmune pathways from childhood adversity to disease. Neurosci. Biobehav. Rev. 80 (2017), 166–184, 10.1016/j.neubiorev.2017.05.020.
137. Kuhlman, K.R., Robles, T.F., Dooley, L.N., Boyle, C.C., Haydon, M.D., Bower, J.E., Within-subject associations between inflammation and features of depression: using the flu vaccine as a mild inflammatory stimulus. Brain Behav. Immun. 69 (2018), 540–547, 10.1016/j.bbi.2018.02.001.
138. Kupfer, D., Harrow, M., Detre, T., Sleep patterns and psychopathology. Acta Psychiatr. Scand. 45 (1969), 75–89.
139. Kupferberg, A., Bicks, L., Hasler, G., Social functioning in major depressive disorder. Neurosci. Biobehav. Rev. 69 (2016), 313–332, 10.1016/j.neubiorev.2016.07.002.
140. Larson, S.J., Dunn, a J., Behavioral effects of cytokines. Brain Behav. Immun. 15 (2001), 371–387, 10.1006/brbi.2001.0643.
141. Lasselin, J., Elsenbruch, S., Lekander, M., Axelsson, J., Karshikoff, B., Grigoleit, J.-S., Engler, H., Schedlowski, M., Benson, S., Mood disturbance during experimental endotoxemia: predictors of state anxiety as a psychological component of sickness behavior. Brain Behav. Immun. 57 (2016), 30–37, 10.1016/j.bbi.2016.01.003.
142. Lasselin, J., Treadway, M.T., Lacourt, T.E., Soop, A., Olsson, M.J., Karshikoff, B., Paues-Göranson, S., Axelsson, J., Dantzer, R., Lekander, M., Lipopolysaccharide alters motivated behavior in a monetary reward task: a randomized trial. Neuropsychopharmacology, 2016, 1–10, 10.1038/npp.2016.191.
143. Lasselin, J., Lekander, M., Axelsson, J., Karshikoff, B., Sex differences in how inflammation affects behavior: what we can learn from experimental inflammatory models in humans. Front. Neuroendocrinol., 2018, 10.1016/j.yfrne.2018.06.005.
144. Lawson, C., MacLeod, C., Hammond, G., Interpretation revealed in the blink of an eye: depressive bias in the resolution of ambiguity. J. Abnorm. Psychol. 111 (2002), 321–328, 10.1037//0021-843X.111.2.321.
145. Lieb, K., Engelbrecht, M.A., Gut, O., Fiebich, B.L., Bauer, J., Janssen, G., Schaefer, M., Cognitive impairment in patients with chronic hepatitis treated with interferon alpha (IFN-a): results from a prospective study. Eur. Psychiatry 21 (2006), 204–210, 10.1016/j.eurpsy.2004.09.030.
146. Lieberman, M.D., Eisenberger, N.I., Pains and pleasures of social life. Sci. Transl. Med. 323 (2009), 890–891, 10.1126/science.1170008.
147. Lisman, J.E., Grace, A.A., The hippocampal-VTA loop: controlling the entry of information into long-term memory. Neuron 46 (2005), 703–713, 10.1016/j.neuron.2005.05.002.
148. Lopez-Duran, N.L., Kovacs, M., George, C.J., Hypothalamic-pituitary-adrenal axis dysregulation in depressed children and adolescents: a meta-analysis. Psychoneuroendocrinology 34 (2009), 1272–1283, 10.1016/j.psyneuen.2009.03.016.
149. Lotrich, F.E., Rabinovitz, M., Gironda, P., Pollock, B.G., Depression following pegylated interferon-alpha: characteristics and vulnerability. J. Psychosom. Res. 63 (2007), 131–135, 10.1016/j.jpsychores.2007.05.013.
150. Majer, M., Welberg, L.A.M., Capuron, L., Pagnoni, G., Raison, C.L., Miller, A.H., IFN-alpha-induced motor slowing is associated with increased depression and fatigue in patients with chronic hepatitis C. Brain Behav. Immun. 22 (2008), 870–880, 10.1016/j.bbi.2007.12.009.
151. Majidi, J., Kosari-Nasab, M., Salari, A.-A., Developmental minocycline treatment reverses the effects of neonatal immune activation on anxiety- and depression-like behaviors, hippocampal inflammation, and HPA axis activity in adult mice. Brain Res. Bull. 120 (2016), 1–13, 10.1016/j.brainresbull.2015.10.009.
152. Malarkey, E.B., Parpura, V., Mechanisms of glutamate release from astrocytes. Neurochem. Int. 52 (2008), 142–154, 10.1016/j.neuint.2007.06.005.
153. Marsland, A.L., Gianaros, P.J., Kuan, D.C., Sheu, L.K., Krajina, K., Manuck, S.B., Brain morphology links systemic inflammation to cognitive function in midlife adults. Brain Behav. Immun., 48, 2015, 195, 10.1016/j.bbi.2015.03.015.
154. Martinot, M.L.P., Bragulat, V., Artiges, E., Dollé F., Hinnen, F., Jouvent, R., Martinot, J.L., Decreased presynaptic dopamine function in the left caudate of depressed patients with affective flattening and psychomotor retardation. Am. J. Psychiatry 158 (2001), 314–316, 10.1176/appi.ajp.158.2.314.
155. Matthews, K.A., Schott, L.L., Bromberger, J.T., Cyranowski, J.M., Everson-Rose, S.A., Sowers, M., Are there bi-directional associations between depressive symptoms and C-reactive protein in mid-life women?. Brain Behav. Immun. 24 (2010), 96–101, 10.1016/j.bbi.2009.08.005.
156. Mayberg, H.S., Positron emission tomography imaging in depression: a neural systems perspective. Neuroimaging Clin. N. Am. 13 (2003), 805–815, 10.1016/S1052-5149(03)00104-7.
157. Mayberg, H.S., Liotti, M., Brannan, S.K., McGinnis, S., Mahurin, R.K., Jerabek, P.A., Silva, J.A., Tekell, J.L., Martin, C.C., Lancaster, J.L., Fox, P.T., Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am. J. Psychiatry 156 (1999), 675–682, 10.1176/ajp.156.5.675.
158. Miller, A.H., Raison, C.L., The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat. Rev. Immunol. 16 (2016), 22–34, 10.1038/nri.2015.5.
159. Miller, G.A., Rockstroh, B., Endophenotypes in psychopathology research: where do we stand?. Annu. Rev. Clin. Psychol. 9 (2013), 177–213, 10.1146/annurev-clinpsy-050212-185540.
160. Miller, A.H., Maletic, V., Raison, C.L., Inflammation and its discontents: the role of cytokines in the pathophysiology of Major Depression. Biol. Psychiatry 65 (2009), 732–741, 10.1016/j.biopsych.2008.11.029.
161. Miller, A.H., Haroon, E., Raison, C.L., Felger, J.C., Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depress. Anxiety 30 (2013), 297–306, 10.1002/da.22084.
162. Moieni, M., Irwin, M.R., Jevtic, I., Olmstead, R., Breen, E.C., Eisenberger, N.I., Sex differences in depressive and socioemotional responses to an inflammatory challenge: implications for sex differences in depression. Neuropsychopharmacology 40 (2015), 1709–1716, 10.1038/npp.2015.17.
163. Moore, S.R., Depue, R.A., Neurobehavioral foundation of environmental reactivity. Psychol. Bull. 142 (2016), 107–164, 10.1037/bul0000028.
164. Morris, B.H., Bylsma, L.M., Rottenberg, J., Does emotion predict the course of major depressive disorder? A review of prospective studies. Br. J. Clin. Psychol. 48 (2009), 255–273, 10.1348/014466508X396549.
165. Morrow, G.R., Hickok, J.T., Roscoe, J.A., Raubertas, R.F., Andrews, P.L.R., Flynn, P.J., Hynes, H.E., Banerjee, T.K., Kirshner, J.J., King, D.K., Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer center Community Clinical Oncology Program. J. Clin. Oncol. 21 (2003), 4635–4641, 10.1200/JCO.2003.04.070.
166. Mullington, J., Korth, C., Hermann, D.M., Orth, A., Galanos, C., Holsboer, F., Pollmächer, T., Dose-dependent effects of endotoxin on human sleep. Am. J. Physiol. Regul. Integr. Comp. Physiol. 278 (2000), R947–55.
167. Muscatell, K.A., Eisenberger, N.I., A social neuroscience perspective on stress and health. Soc. Personal. Psychol. Compass 6 (2012), 890–904, 10.1111/j.1751-9004.2012.00467.x.
168. Muscatell, K.A., Moieni, M., Inagaki, T.K., Dutcher, J.M., Jevtic, I., Breen, E.C., Irwin, M.R., Eisenberger, N.I., Exposure to an inflammatory challenge enhances neural sensitivity to negative and positive social feedback. Brain Behav. Immun. 57 (2016), 21–29, 10.1016/j.bbi.2016.03.022.
169. Musselman, D.L., Lawson, D.H., Gumnick, J.F., Manatunga, A.K., Penna, S., Goodkin, R.S., Greiner, K., Nemeroff, C.B., Miller, A.H., Paroxetine for the prevention of depression induced by high-dose interferon alpha. N. Engl. J. Med. 344 (2001), 961–966.
170. Myin-Germeys, I., Peeters, F., Havermans, R., Nicolson, N.A., deVries, M.W., Delespaul, P., van Os, J., Emotional reactivity to daily life stress in psychosis and affective disorder: an experience sampling study. Acta Psychiatr. Scand. 107 (2003), 124–131, 10.1034/j.1600-0447.2003.02025.x.
171. Nair, A., Bonneau, R.H., Stress-induced elevation of glucocorticoids increases microglia proliferation through NMDA receptor activation. J. Neuroimmunol., 171, 2006, 72, 10.1016/j.jneuroim.2005.09.012.
172. Nemeroff, C.B., Prevalence and management of treatment-resistant depression. J. Clin. Psychiatry 68 (2007), 17–25.
173. Nestler, E.J., Carlezon, W.A., The mesolimbic dopamine reward circuit in depression. Biol. Psychiatry 59 (2006), 1151–1159, 10.1016/j.biopsych.2005.09.018.
174. Nikkheslat, N., Pariante, C.M., Zunszain, P.A., Chapter 3 - neuroendocrine abnormalities in Major depression: an insight into glucocorticoids, cytokines, and the kynurenine pathway. Baune, B.T., (eds.) Inflammation and Immunity in Depression, 2018, Academic Press, 45–60, 10.1016/B978-0-12-811073-7.00003-9.
175. Nolen-Hoeksema, S., Sex differences in unipolar depression: evidence and theory. Psychol. Bull. 101 (1987), 259–282, 10.1037/0033-2909.101.2.259.
176. Nolen-Hoeksema, S., Gender differences in depression. Curr. Dir. Psychol. Sci. 10 (2001), 173–176, 10.1111/1467-8721.00142.
177. Nutt, D., Demyttenaere, K., Janka, Z., Aarre, T., Bourin, M., Canonico, P.L., Carrasco, J.L., Stahl, S., The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J. Psychopharmacol. Oxf. Engl. 21 (2007), 461–471, 10.1177/0269881106069938.
178. O'Connor, J.C., Lawson, M.A., André C., Moreau, M., Lestage, J., Castanon, N., Kelley, K.W., Dantzer, R., Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol. Psychiatry 14 (2009), 511–522, 10.1038/sj.mp.4002148.
179. O'Farrell, K., Harkin, A., Stress-related regulation of the kynurenine pathway: relevance to neuropsychiatric and degenerative disorders. Neuropharmacol. Kynurenine Pathway Health Dis. 112 (2017), 307–323, 10.1016/j.neuropharm.2015.12.004.
180. Paine, N.J., Ring, C., Bosch, J.A., Drayson, M.T., Veldhuijzen van Zanten, J.J.C.S., The time course of the inflammatory response to the Salmonella typhi vaccination. Brain Behav. Immun. 30 (2013), 73–79, 10.1016/j.bbi.2013.01.004.
181. Palagini, L., Baglioni, C., Ciapparelli, A., Gemignani, A., Riemann, D., REM sleep dysregulation in depression: state of the art. Sleep Med. Rev. 17 (2013), 377–390, 10.1016/j.smrv.2012.11.001.
182. Pariante, C.M., Lightman, S.L., The HPA axis in major depression: classical theories and new developments. Trends Neurosci. 31 (2008), 464–468, 10.1016/j.tins.2008.06.006.
183. Pavol, M.A., Meyers, C.A., Rexer, J.L., Valentine, A.D., Mattis, P.J., Talpaz, M., Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Neurology 45 (1995), 947–950, 10.1212/WNL.45.5.947.
184. Pecchi, E., Dallaporta, M., Jean, A., Thirion, S., Troadec, J.D., Prostaglandins and sickness behavior: old story, new insights. Physiol. Behav. 97 (2009), 279–292, 10.1016/j.physbeh.2009.02.040.
185. Piet, J., Hougaard, E., The effect of mindfulness-based cognitive therapy for prevention of relapse in recurrent major depressive disorder: a systematic review and meta-analysis. Clin. Psychol. Rev. 31 (2011), 1032–1040, 10.1016/j.cpr.2011.05.002.
186. Pizzagalli, D.A., Iosifescu, D., Hallett, L.A., Ratner, K.G., Fava, M., Reduced hedonic capacity in major depressive disorder: evidence from a probabilistic reward task. J. Psychiatr. Res. 43 (2008), 76–87, 10.1016/j.jpsychires.2008.03.001.
187. Pizzagalli, D.A., Holmes, A.J., Dillon, D.G., Goetz, E.L., Birk, J.L., Bogdan, R., Dougherty, D.D., Iosifescu, D.V., Rauch, S.L., Fava, M., Reduced caudate and nucleus accumbens response to rewards in unmedicated subjects with major depressive disorder. Am. J. Psychiatry 166 (2009), 702–710, 10.1176/appi.ajp.2008.08081201.Reduced.
188. Qin, L., Wu, X., Block, M.L., Liu, Y., Breese, G.R., Hong, J.-S., Knapp, D.J., Crews, F.T., Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 55 (2007), 453–462, 10.1002/glia.20467.
189. Raison, C.L., The promise and limitations of anti-inflammatory agents for the treatment of Major Depressive Disorder. Curr. Top. Behav. Neurosci. 31 (2017), 287–302, 10.1007/7854_2016_26.
190. Raison, C.L., Miller, A.H., Is depression an inflammatory disorder?. Curr. Psychiatry Rep. 13 (2011), 467–475, 10.1007/s11920-011-0232-0.
191. Raison, C.L., Demetrashvili, M., Capuron, L., Miller, A.H., Neuropsychiatric adverse effects of interferon-alpha. CNS Drugs 19 (2005), 105–123, 10.2165/00023210-200519020-00002.
192. Raison, C.L., Capuron, L., Miller, A.H., Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 27 (2006), 24–31, 10.1016/j.it.2005.11.006.
193. Raison, C.L., Rye, D.B., Woolwine, B.J., Vogt, G.J., Bautista, B.M., Spivey, J.R., Miller, A.H., Chronic interferon-alpha administration disrupts sleep continuity and depth in patients with hepatitis C: association with fatigue, motor slowing, and increased evening cortisol. Biol. Psychiatry 68 (2010), 942–949, 10.1016/j.biopsych.2010.04.019.
194. Raison, C.L., Rutherford, R.E., Woolwine, B.J., Shuo, C., Schettler, P., Drake, D.F., Haroon, E., Miller, A.H., A randomized controlled trial of the tumor necrosis factor-alpha antagonist infliximab in treatment resistant depression: role of baseline inflammatory biomarkers. JAMA Psychiatry 70 (2013), 31–41, 10.1001/2013.jamapsychiatry.4.
195. Reichenberg, A., Yirmiya, R., Schuld, A., Kraus, T., Haack, M., Morag, A., Pollmächer, T., Cytokine-associated emotional and cognitive disturbances in humans. Arch. Gen. Psychiatry 58 (2001), 445–452, 10.1001/archpsyc.58.5.445.
196. Reinert, K.R.S., Umphlet, C.D., Quattlebaum, A., Boger, H.A., Short-term effects of an endotoxin on substantia nigra dopamine neurons. Brain Res. 1557 (2014), 164–170, 10.1016/j.brainres.2014.02.005.
197. Rethorst, C.D., Bernstein, I., Trivedi, M.H., Inflammation, obesity, and metabolic syndrome in depression: analysis of the 2009-2010 National Health and Nutrition Examination Survey (NHANES). J. Clin. Psychiatry 75 (2014), e1428–32, 10.4088/JCP.14m09009.
198. Riemann, D., Berger, M., Voderholzer, U., Sleep and depression–results from psychobiological studies: an overview. Biol. Psychol. 57 (2001), 67–103, 10.1016/S0301-0511(01)00090-4.
199. Robaeys, G., De Bie, L., Wichers, M.C., Bruckers, L., Nevens, F., Michielsen, P., Van Ranst, M., Buntinx, F., Early prediction of major depression in chronic hepatitis C patients during peg-interferon alpha-2b treatment by assessment of vegetative-depressive symptoms after four weeks. World J. Gastroenterol. 13 (2007), 5736–5740, 10.3748/wjg.v13.i43.5736.
200. Rogers, D., Lees, A.J., Smith, E., Trimble, M., Stern, G.M., Bradyphrenia in Parkinson's disease and psychomotor retardation in depressive illness. An experimental study. Brain J. Neurol. 110:Pt 3 (1987), 761–776.
201. Rude, S.S., Wenzlaff, R.M., Gibbs, B., Vane, J., Whitney, T., Negative processing biases predict subsequent depressive symptoms. Cogn. Emot. 16 (2002), 423–440, 10.1080/02699930143000554.
202. Sacher, J., Neumann, J., Fünfstück, T., Soliman, A., Villringer, A., Schroeter, M.L., Mapping the depressed brain: a meta-analysis of structural and functional alterations in major depressive disorder. J. Affect. Disord. 140 (2012), 142–148, 10.1016/j.jad.2011.08.001.
203. Sanislow, C.A., Pine, D.S., Quinn, K.J., Kozak, M.J., Garvey, M.A., Heinssen, R.K., Wang, P.S.-E., Cuthbert, B.N., Developing constructs for psychopathology research: research domain criteria. J. Abnorm. Psychol. 119 (2010), 631–639, 10.1037/a0020909.
204. Schmittmann, V.D., Cramer, A.O.J., Waldorp, L.J., Epskamp, S., Kievit, R.A., Borsboom, D., Deconstructing the construct: a network perspective on psychological phenomena. New Ideas Psychol. 31 (2011), 43–53, 10.1016/j.newideapsych.2011.02.007.
205. Schwarz, J.M., Sholar, P.W., Bilbo, S.D., Sex differences in microglial colonization of the developing rat brain. J. Neurochem. 120 (2012), 948–963.
206. Shah, P.J., Ogilvie, A.D., Goodwin, G.M., Ebmeier, K.P., Clinical and psychometric correlates of dopamine D2 binding in depression. Psychol. Med. (Paris) 27 (1997), 1247–1256, 10.1017/S0033291797005382.
207. Shea, M.T., Elkin, I., Imber, S.D., Sotsky, S.M., Watkins, J.T., Collins, J.F., Pilkonis, P.A., Beckham, E., Glass, D.R., Dolan, R.T., Parloff, M.B., Course of depressive symptoms over follow-up: findings from the national institute of mental health treatment of depression collaborative research program. Arch. Gen. Psychiatry 49 (1992), 782–787, 10.1001/archpsyc.1992.01820100026006.
208. Siegle, G.J., Steinhauer, S.R., Thase, M.E., Stenger, V.A., Carter, C.S., Can't shake that feeling: assessment of sustained event-related fMRI amygdala activity in response to emotional information in depressed individuals. Biol. Psychiatry 51 (2002), 693–707, 10.1016/S0006-3223(02)01314-8.
209. Simons, C.J.P., Jacobs, N., Derom, C., Thiery, E., Jolles, J., Van Os, J., Krabbendam, L., Cognition as predictor of current and follow-up depressive symptoms in the general population. Acta Psychiatr. Scand. 120 (2009), 45–52, 10.1111/j.1600-0447.2008.01339.x.
210. Slavich, G.M., Irwin, M.R., From stress to inflammation and major depressive disorder: a social signal transduction theory of depression. Psychol. Bull. 140 (2014), 774–815, 10.1037/a0035302.
211. Sloan, D.M., Strauss, M.E., Quirk, S.W., Sajatovic, M., Subjective and expressive emotional responses in depression. J. Affect. Disord. 46 (1997), 135–141, 10.1016/S0165-0327(97)00097-9.
212. Sloan, D.M., Strauss, M.E., Wisner, K.L., Diminished response to pleasant stimuli by depressed women. J. Abnorm. Psychol. 110 (2001), 488–493, 10.1037/0021-843X.110.3.488.
213. Snyder, H.R., Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: a meta-analysis and review. Psychol. Bull. 139 (2014), 81–132, 10.1037/a0028727.Major.
214. Stevens, F.L., Hurley, R.A., Taber, K.H., Anterior cingulate cortex: unique role in cognition and emotion. J. Neuropsychiatry Clin. Neurosci. 23 (2011), 121–125, 10.1176/jnp.23.2.jnp121.
215. Stewart, J.C., Rand, K.L., Muldoon, M.F., Kamarck, T.W., A prospective evaluation of the directionality of the depression–inflammation relationship. Brain Behav. Immun. 23 (2009), 936–944, 10.1016/j.bbi.2009.04.011.
216. Stuhrmann, A., Dohm, K., Kugel, H., Zwanzger, P., Redlich, R., Grotegerd, D., Rauch, A.V., Arolt, V., Heindel, W., Suslow, T., Zwitserlood, P., Dannlowski, U., Mood-congruent amygdala responses to subliminally presented facial expressions in major depression: associations with anhedonia. J. Psychiatry Neurosci. JPN 38 (2013), 249–258, 10.1503/jpn.120060.
217. Swardfager, W., Rosenblat, J.D., Benlamri, M., McIntyre, R.S., Mapping inflammation onto mood: inflammatory mediators of anhedonia. Neurosci. Biobehav. Rev. 64 (2016), 148–166, 10.1016/j.neubiorev.2016.02.017.
218. Targum, S.D., Fava, M., Fatigue as a residual symptom of depression. Innov. Clin. Neurosci. 8 (2011), 40–43.
219. Taylor, J.L., Grossberg, S.E., The effects of interferon-alpha on the production and action of other cytokines. Semin. Oncol. 25 (1998), 23–29.
220. Taylor, B.P., Bruder, G.E., Stewart, J.W., McGrath, P.J., Halperin, J., Ehrlichman, H., Quitkin, F.M., Psychomotor slowing as a predictor of fluoxetine nonresponse in depressed outpatients. Am. J. Psychiatry 163 (2006), 73–78, 10.1176/appi.ajp.163.1.73.
221. Treadway, M.T., Buckholtz, J.W., Schwartzman, A.N., Lambert, W.E., Zald, D.H., Worth the “EEfRT”? The effort expenditure for rewards task as an objective measure of motivation and anhedonia. PLoS One 4 (2009), 1–9, 10.1371/journal.pone.0006598.
222. Treadway, M.T., Zald, D.H., Reconsidering anhedonia in depression: lessons from translational neuroscience. Neurosci. Biobehav. Rev. 35 (2011), 537–555, 10.1016/j.neubiorev.2010.06.006.
223. Tremblay, L.K., Naranjo, C.A., Graham, S.J., Herrmann, N., Mayberg, H.S., Hevenor, S.J., Busto, U.E., Functional neuroanatomical substrates of altered reward processing in major depressive disorder revealed by a dopaminergic probe. Arch. Gen. Psychiatry 62 (2005), 1228–1236, 10.1001/archpsyc.62.11.1228.
224. Tsai, M.Y., Hanson, N.Q., Straka, R.J., Hoke, T.R., Ordovas, J.M., Peacock, J.M., Arends, V.L., Arnett, D.K., Effect of influenza vaccine on markers of inflammation and lipid profile. J. Lab. Clin. Med. 145 (2005), 323–327, 10.1016/j.lab.2005.03.009.
225. Tsuno, N., Besset, A., Ritchie, K., Sleep and depression. J. Clin. Psychiatry 66 (2005), 1254–1269, 10.4088/JCP.v66n1008.
226. Tylee, A., Gastpar, M., Lépine, J.P., Mendlewicz, J., Identification of depressed patient types in the community and their treatment needs: findings from the DEPRES II (Depression Research in European Society II) survey. DEPRES Steering Committee. Int. Clin. Psychopharmacol. 14 (1999), 153–165.
227. Tynan, R.J., Naicker, S., Hinwood, M., Nalivaiko, E., Buller, K.M., Pow, D.V., Day, T.A., Walker, F.R., Chronic stress alters the density and morphology of microglia in a subset of stress-responsive brain regions. Brain Behav. Immun., 24, 2010, 1058, 10.1016/j.bbi.2010.02.001.
228. Valkanova, V., Ebmeier, K.P., Allan, C.L., CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies. J. Affect. Disord. 150 (2013), 736–744, 10.1016/j.jad.2013.06.004.
229. van den Biggelaar, A.H.J., Gussekloo, J., de Craen, A.J.M., Frölich, M., Stek, M.L., van der Mast, R.C., Westendorp, R.G.J., Inflammation and interleukin-1 signaling network contribute to depressive symptoms but not cognitive decline in old age. Exp. Gerontol. 42 (2007), 693–701, 10.1016/j.exger.2007.01.011.
230. van den Boogaard, M., Ramakers, B.P., van Alfen, N., van der Werf, S.P., Fick, W.F., Hoedemaekers, C.W., Verbeek, M.M., Schoonhoven, L., van der Hoeven, J.G., Pickkers, P., Endotoxemia-induced inflammation and the effect on the human brain. Crit. Care Lond. Engl., 14, 2010, R81, 10.1186/cc9001.
231. van Praag, H.M., Korf, J., Retarded depression and the dopamine metabolism. Psychopharmacologia 19 (1971), 199–203, 10.1007/BF00402643.
232. Vgontzas, A.N., Bixler, E.O., Lin, H.-M., Prolo, P., Trakada, G., Chrousos, G.P., IL-6 and its circadian secretion in humans. Neuroimmunomodulation 12 (2005), 131–140, 10.1159/000084844.
233. Videbech, P., Ravnkilde, B., Pedersen, T.H., Hartvig, H., Egander, A., Clemmensen, K., Rasmussen, N.A., Andersen, F., Gjedde, A., Rosenberg, R., The Danish PET/depression project: clinical symptoms and cerebral blood flow. A regions-of-interest analysis. Acta Psychiatr. Scand. 106 (2002), 35–44.
234. Vittengl, J.R., Clark, L.A., Dunn, T.W., Jarrett, R.B., Reducing relapse and recurrence in unipolar depression: a comparative meta-analysis of cognitive–behavioral therapy's effects. J. Consult. Clin. Psychol., 75, 2007, 475.
235. Wacker, J., Dillon, D.G., Pizzagalli, D.A., The role of the nucleus accumbens and rostral anterior cingulate cortex in anhedonia: integration of resting EEG, fMRI, and volumetric techniques. Neuroimage 46 (2009), 327–337, 10.1016/j.neuroimage.2009.01.058.
236. Walker, E.A., Katon, W.J., Jemelka, R.P., Psychiatric disorders and medical care utilization among people in the general population who report fatigue. J. Gen. Intern. Med. 8 (1993), 436–440, 10.1007/BF02599621.
237. Webb, C.A., Dillon, D.G., Pechtel, P., Goer, F.K., Murray, L., Huys, Q.J., Fava, M., McGrath, P.J., Weissman, M., Parsey, R., Kurian, B.T., Adams, P., Weyandt, S., Trombello, J.M., Grannemann, B., Cooper, C.M., Deldin, P., Tenke, C., Trivedi, M., Bruder, G., Pizzagalli, D.A., Neural Correlates of three promising endophenotypes of depression: evidence from the EMBARC study. Neuropsychopharmacology 41 (2016), 454–463, 10.1038/npp.2015.165.
238. Weinstein, A.A., Ph, D., Deuster, P.A., Francis, J.L., Robert, W., Tracy, R.P., Kop, W.J., Acute mental stress in depression. Russell J. Bertrand Russell Arch. 84 (2010), 228–234, 10.1016/j.biopsycho.2010.01.016.Neurohormonal.
239. WHO Depression, Who. 2017 (Accessed 11.2.17) http://www.who.int/mediacentre/factsheets/fs369/en/.
240. Wichers, M.C., Koek, G.H., Robaeys, G., Praamstra, A.J., Maes, M., Early increase in vegetative symptoms predicts IFN-alpha-induced cognitive-depressive changes. Psychol. Med. (Paris) 35 (2005), 433–441, 10.1017/S0033291704003526.
241. Winer, E.S., Salem, T., Reward devaluation: dot-probe meta-analytic evidence of avoidance of positive information in depressed persons. Psychol. Bull. 142 (2015), 18–78, 10.1037/bul0000022.
242. Wium-Andersen, M.K., Ørsted, D.D., Nielsen, S.F., Nordestgaard, B.G., Elevated C-reactive protein levels, psychological distress, and depression in 73,131 individuals. JAMA Psychiatry, 70, 2013, 176, 10.1001/2013.jamapsychiatry.102.
243. Wright, C.E., Strike, P.C., Brydon, L., Steptoe, A., Acute inflammation and negative mood: mediation by cytokine activation. Brain Behav. Immun. 19 (2005), 345–350, 10.1016/j.bbi.2004.10.003.
244. Yirmiya, R., Goshen, I., Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav. Immun. 25 (2011), 181–213, 10.1016/j.bbi.2010.10.015.
245. Young, J.J., Bruno, D., Pomara, N., A review of the relationship between proinflammatory cytokines and major depressive disorder. J. Affect. Disord. 169 (2014), 15–20, 10.1016/j.jad.2014.07.032.
246. Zunszain, P.A., Anacker, C., Cattaneo, A., Choudhury, S., Musaelyan, K., Myint, A.M., Thuret, S., Price, J., Pariante, C.M., Interleukin-1β: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis. Neuropsychopharmacology 37 (2012), 939–949, 10.1038/npp.2011.277.